Komori
Earnings presentation2934J Frontier Co.,Ltd.Food

Briefing Materials on Financial Results for the Third Quarter of the Fiscal Year Ending May 2026

In the third quarter of the fiscal year ending May 2026, quarterly standalone revenue, EBITDA, operating profit and ordinary profit all exceeded the year-earlier period and reached record highs. On a cumulative basis, operating profit, ordinary profit and net income are progressing well against the full-year forecasts.

Worth reading
43Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
155.9
Year-on-year change in operating profit (%)
Wording
Conditional
How definitive the wording is.

Contents of this document

Earnings presentationThird quarter of the fiscal year ending May 20267 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥16,381 million
Operating profit¥304 million
Ordinary income¥351 million
Net income¥84 million net income attributable to owners of the parent
Operating profit margin
Rate1.9%
Results for the three months of the current quarter
Net Sales
¥5,706 million+3.6%
EBITDA
¥613 million+88.1%
Operating profit
¥447 million+155.9%
Ordinary income
¥483 million+186.5%
Profit attributable to owners of the parent
¥275 million+93.4%
Full-year earnings forecast
Net Sales
¥23,600 million
EBITDA
¥1,015 million
Operating profit
¥327 million
Ordinary income
¥240 million
Profit attributable to owners of the parent
¥100 million
By segment
Medical Care Sales business
Net Sales
¥5,850 million
EBITDA
¥762 million
Healthcare Sales business
Net Sales
¥6,850 million
EBITDA
¥485 million
Healthcare Marketing business
Net Sales
¥10,900 million
EBITDA
¥439 million
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales69.4%
EBITDA76.6%
Operating profit93.1%
Ordinary income146.5%
Profit attributable to owners of the parent84.4%
By segment
Medical Care Sales business
Net Sales67.2%
EBITDA55.3%
Healthcare Sales business
Net Sales60.6%
EBITDA83.0%
Healthcare Marketing business
Net Sales76.2%
EBITDA53.9%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
As planned; margins improved significantly / progressing smoothly
New initiatives
  • Partnership agreement with Kinki Nippon Tourist
  • Free coupon campaign for pickup at PUDO lockers inside Seven-Eleven stores
  • Opening of the official SOKUYAKU Wellness store on Qoo10
  • Official sponsorship agreement between ウェルヴィーナス and the Hokkaido Nippon-Ham Fighters
  • Start of general sales of TOCASSE
Key KPIsA metric the company considers important as a management benchmark.
  • QAU (quarterly active users)31 10,000 people
  • ARR (annual recurring revenue)¥101 million
  • Cumulative sales of the 酵水素328選 series1,230 10,000 units
  • TOCASSE sales on the first day of launch1,000 units
  • Sales at the 19th eCommerce Fair¥4,000 10,000
Segment results
  • Medical Care Sales business
    Net Sales¥3,928 million
    Profit¥421 million (EBITDA)
  • Healthcare Sales business
    Net Sales¥4,149 million
    Profit¥402 million (EBITDA)
  • Healthcare Marketing business
    Net Sales¥8,303 million
    Profit¥236 million (EBITDA)
Medium-term management plan targets
Deepen the SOKUYAKU healthcare economic zone in Japan and create the same economic zone in the Asian market. Target year: Not disclosed.
Market Size / Share
  • DetailsJapan's online medical consultation market
    FiguresMarket size trends from 2022 to 2028
  • DetailsGlobal Telemedicine Market
    Figures15.2 in 2020, 60.1 in 2028, etc.
Number of stores and locations
Number at period-endPUDO lockers at 1,062 Seven-Eleven stores
Contents of this document
ItemDetails
Document typeEarnings presentation
Fiscal Period CoveredThird quarter of the fiscal year ending May 2026
Net Sales¥16,381 million
Operating profit¥304 million
Ordinary income¥351 million
Net income¥84 million (net income attributable to owners of the parent)
Operating profit marginRate 1.9% / Year-on-year change (points) Not disclosed
Results for the three months of the current quarterNet Sales ¥5,706 million (YoY +3.6%) / EBITDA ¥613 million (YoY +88.1%) / Operating profit ¥447 million (YoY +155.9%) / Ordinary income ¥483 million (YoY +186.5%) / Profit attributable to owners of the parent ¥275 million (YoY +93.4%)
Full-year earnings forecastNet Sales ¥23,600 million / EBITDA ¥1,015 million / Operating profit ¥327 million / Ordinary income ¥240 million / Profit attributable to owners of the parent ¥100 million / By segment Medical Care Sales business Net Sales ¥5,850 million / EBITDA ¥762 million / Healthcare Sales business Net Sales ¥6,850 million / EBITDA ¥485 million / Healthcare Marketing business Net Sales ¥10,900 million / EBITDA ¥439 million
Progress against full-year forecastNet Sales 69.4% / EBITDA 76.6% / Operating profit 93.1% / Ordinary income 146.5% / Profit attributable to owners of the parent 84.4% / By segment Medical Care Sales business Net Sales 67.2% / EBITDA 55.3% / Healthcare Sales business Net Sales 60.6% / EBITDA 83.0% / Healthcare Marketing business Net Sales 76.2% / EBITDA 53.9%
Self-assessment against the planAs planned; margins improved significantly / progressing smoothly
Segment resultsSegment Medical Care Sales business / Net Sales ¥3,928 million / Profit ¥421 million (EBITDA) / Year on year against the same period last year Not disclosed, Segment Healthcare Sales business / Net Sales ¥4,149 million / Profit ¥402 million (EBITDA) / Year on year against the same period last year Not disclosed, Segment Healthcare Marketing business / Net Sales ¥8,303 million / Profit ¥236 million (EBITDA) / Year on year against the same period last year Not disclosed
Key KPIsIndicator name QAU (quarterly active users) / Value 31 10,000 people / Year on year against the same period last year Not disclosed, Indicator name ARR (annual recurring revenue) / Value ¥101 million / Year on year against the same period last year Not disclosed, Indicator name Cumulative sales of the 酵水素328選 series / Value 1,230 10,000 units / Year on year against the same period last year Not disclosed, Indicator name TOCASSE sales on the first day of launch / Value 1,000 units / Year on year against the same period last year Not disclosed, Indicator name Sales at the 19th eCommerce Fair / Value ¥4,000 10,000 / Year on year against the same period last year Not disclosed
Number of stores and locationsNumber at period-end PUDO lockers at 1,062 Seven-Eleven stores / Number of store openings and closures during the period Not disclosed
Medium-term management plan targetsDeepen the SOKUYAKU healthcare economic zone in Japan and create the same economic zone in the Asian market. Target year: Not disclosed.
Market Size / ShareDetails Japan's online medical consultation market / Figures Market size trends from 2022 to 2028, Details Global Telemedicine Market / Figures 15.2 in 2020, 60.1 in 2028, etc.
New initiativesPartnership agreement with Kinki Nippon Tourist, Free coupon campaign for pickup at PUDO lockers inside Seven-Eleven stores, Opening of the official SOKUYAKU Wellness store on Qoo10, Official sponsorship agreement between ウェルヴィーナス and the Hokkaido Nippon-Ham Fighters, Start of general sales of TOCASSE
Items this document does not state (14)
Gross Profit MarginSelling, general and administrative expensesBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The increase in SOKUYAKU usage driven by colds, influenza and hay fever, the progress made in introducing SOKUYAKU Benefit for corporate customers, and the creation of B2B revenue streams, including the incorporation of SOKUYAKU into Kinki Nippon Tourist's school excursion plans, contributed to the results. Profitability also improved in the pharmaceutical D2C business and the D2C businesses for health foods, cosmetics and other products, due to the effects of advertising investment and other initiatives conducted in the first half to acquire new subscription customers.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Briefing Materials on Financial Results for the Third Quarter of the Fiscal Year Ending May 2026 | J Frontier Co.,Ltd. (2934) timely disclosure | Komori